Close Menu

NEW YORK – Boston-based NanoView Biosciences said today that it has signed an exclusive agreement with Alfatest, headquartered in Rome, to distribute its ExoView platform in Italy.

The research-use-only ExoView platform is an antibody labeling and imaging-based extracellular vesicle detection system that provides size analysis, vesicle count, phenotyping, and biomarker colocalization. According to the company, it requires minimal sample input, no sample prep or purification, and can be used directly with complex biological samples.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

Washington Post columnist writes that she is skeptical about DNA-based diets.

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.